These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

785 related items for PubMed ID: 25193543

  • 1. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
    Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z, Nielsen TO.
    Breast Cancer Res; 2014 Sep 06; 16(5):432. PubMed ID: 25193543
    [Abstract] [Full Text] [Related]

  • 2. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
    Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA.
    Hum Pathol; 2013 Oct 06; 44(10):2055-63. PubMed ID: 23701942
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.
    Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO.
    Breast Cancer Res; 2012 Mar 15; 14(2):R48. PubMed ID: 22420471
    [Abstract] [Full Text] [Related]

  • 6. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
    Ahmadvand S, Faghih Z, Montazer M, Safaei A, Mokhtari M, Jafari P, Talei AR, Tahmasebi S, Ghaderi A.
    Cell Oncol (Dordr); 2019 Jun 15; 42(3):343-356. PubMed ID: 30825183
    [Abstract] [Full Text] [Related]

  • 7. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon KA, Nielsen TO.
    JAMA Oncol; 2017 Nov 09; 3(11):e172085. PubMed ID: 28750133
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH.
    Am J Clin Oncol; 2013 Jun 09; 36(3):224-31. PubMed ID: 22495453
    [Abstract] [Full Text] [Related]

  • 11. A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis.
    Papaioannou E, Sakellakis M, Melachrinou M, Tzoracoleftherakis E, Kalofonos H, Kourea E.
    Anticancer Res; 2019 Mar 09; 39(3):1217-1232. PubMed ID: 30842152
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T, Hida AI, Inoue N, Imamura M, Fujimoto Y, Akazawa K, Hirota S, Miyoshi Y.
    Breast Cancer Res Treat; 2018 Feb 09; 168(1):135-145. PubMed ID: 29168063
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
    Fukui R, Watanabe T, Morimoto K, Fujimoto Y, Nagahashi M, Ishikawa E, Hirota S, Miyoshi Y.
    Breast Cancer; 2023 Sep 09; 30(5):703-713. PubMed ID: 37115435
    [Abstract] [Full Text] [Related]

  • 16. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.
    Droeser R, Zlobec I, Kilic E, Güth U, Heberer M, Spagnoli G, Oertli D, Tapia C.
    BMC Cancer; 2012 Apr 03; 12():134. PubMed ID: 22471961
    [Abstract] [Full Text] [Related]

  • 17. High tumor-infiltrating FoxP3+ T cells predict poor survival in estrogen receptor-positive breast cancer: A meta-analysis.
    Qian F, Qingping Y, Linquan W, Xiaojin H, Rongshou W, Shanshan R, Wenjun L, Yong H, Enliang L.
    Eur J Surg Oncol; 2017 Jul 03; 43(7):1258-1264. PubMed ID: 28214052
    [Abstract] [Full Text] [Related]

  • 18. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
    Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, Yin D, Gu F, Yao Z, Fu L.
    Breast Cancer Res Treat; 2011 Nov 03; 130(2):645-55. PubMed ID: 21717105
    [Abstract] [Full Text] [Related]

  • 19. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
    Tsang JY, Hui SW, Ni YB, Chan SK, Yamaguchi R, Kwong A, Law BK, Tse GM.
    Breast Cancer Res Treat; 2014 Jan 03; 143(1):1-9. PubMed ID: 24272079
    [Abstract] [Full Text] [Related]

  • 20. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.
    Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelves C, Bartlett JM, Mahmoud SM, Rakha E, Ellis IO, Liu S, Gao D, Nielsen TO, Pharoah PD, Caldas C.
    Ann Oncol; 2014 Aug 03; 25(8):1536-43. PubMed ID: 24915873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.